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in any medium, provided the original work is properly citeA third of patients with critical limb ischemia (CLI) will eventually require limb
amputation. Therapeutic neovascularization using unselected mononuclear cells to
salvage ischemic limbs has produced modest results. The TIE2-expressing mono-
cytes/macrophages (TEMs) are a myeloid cell subset known to be highly angiogenic in
tumours. This study aimed to examine the kinetics of TEMs in patients with CLI and
whether these cells promote neovascularization of the ischemic limb. Here we show
that there are 10-fold more circulating TEMs in CLI patients, and removal of ischemia
reduces their numbers to normal levels. TEM numbers in ischemic muscle are two-
fold greater than normoxic muscle from the same patient. TEMs from patients with
CLI display greater proangiogenic activity than TIE2-negative monocytes in vitro.
Using a mouse model of hindlimb ischemia, lentiviral-based Tie2 knockdown in TEMs
impaired recovery from ischemia, whereas delivery of mouse macrophages over-
expressing TIE2, or human TEMs isolated from CLI patients, rescued limb ischemia.
These data suggest that enhancing TEM recruitment to the ischemic muscle may
have the potential to improve limb neovascularization in CLI patients.vision, King’s College
al Research Centre at
’s College London, UK
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Peripheral arterial occlusive disease (PAOD) affects one in
five individuals over the age of 75 (Berger and Hiatt, 2012).
The spectrum of PAOD ranges from intermittent claudication
to critical limb ischemia (CLI). The latter results from
severe restriction of blood flow and manifests as constant
and intractable pain, often with ulceration or gangrene
of the limb (Norgren et al, 2007; Varu et al, 2010).
Conventional interventions for this condition include arterial
bypass surgery or endovascular therapies such as balloon
angioplasty and stenting (Norgren et al, 2007; Varu et al,
2010). A significant proportion of patients with CLI are,
however, not amenable to these treatments and up to a fifth
will require amputation of the limb within a year (Marston
et al, 2006). The quality of life of patients with CLI is similar
to those with terminal cancer (Albers et al, 1992) underlining
the need for more effective revascularization strategies in
these patients.is an open access article under
se, distribution and reproduction
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Age (range) 73 (59–91) 72 (58–88) 35 (21–38)
Male 23 (66%) 13 (65%) 21 (60%)
Positive smoking history 34 (85%) 15 (75%) 7 (35%)
Hypertension 31 (78%) 15 (75%) 0
Hyperlipidemia 25 (63%) 11 (55%) 0
Diabetes 5 (13%) 3 (15%) 0





Mean ABPI sem 0.40.09
No significant difference in demographics between the two groups (CLI vs.
age-matched controls, p> 0.05 by Fisher’s exact test). Rutherford scores: 4:
ischemic rest pain; 5: rest pain with minor tissue loss; 6: rest pain with major
tissue loss. ABPI: ankle:brachial artery pressure index (a measure of restriction
to blood flow in peripheral arterial disease where a ratio of 1.0 suggests
normal flow).Therapeutic neovascularization has been hailed as a
promising treatment for patients who cannot be revascularized
using conventional methods, but the majority of clinical
studies that have used angiogenic growth factors alone have
reported limited efficacy (Belch et al, 2011; Lederman et al,
2002; Rajagopalan et al, 2003). This has stimulated investiga-
tions into the utility of cell-based therapy as a means of
sustained production of the complex mixture of growth factors
required for robust, efficacious revascularization, but results
obtained after injection of unselected bone marrow (BM) or
peripheral blood-derived mononuclear cell isolates have also
been equivocal (Fadini et al, 2010; Moazzami et al, 2011). This
may have resulted from ‘dilution’ of the delivered angiogenic
cells in these mixed cell populations. Identification and selective
delivery of a specific, potent angiogenic cell population may,
therefore, be the key to developing more efficacious treatments
(Losordo and Dimmeler, 2004).
In pre-clinical models, there is strong evidence to show that
TIE2-expressing monocytes/macrophages (TEMs) support
angiogenesis in tumours and remodelling tissues (Capobianco
et al, 2011; Coffelt et al, 2010; De Palma et al, 2005; Fantin et al,
2010; He et al, 2012; Mazzieri et al, 2011; Modarai et al, 2005;
Pucci et al, 2009), but there is a paucity of data linking this cell
type to pathologies in patients. Work in animal models suggests
that their role is to provide paracrine support for angiogenesis by
cross-talking with, or bridging endothelial cells to aid tip-cell
fusion (Fantin et al, 2010; Mazzieri et al, 2011). Specific
depletion of TEMs (Capobianco et al, 2011; De Palma et al, 2005)
or conditional Tie2 knockdown in these cells (Mazzieri et al,
2011) inhibits tumour angiogenesis, which supports the notion
that TEMs represent an important angiogenic drive in these
pathological tissues. A recent clinical study also showed that
circulating TEMs are increased in hepatocellular carcinoma
patients and preferentially localize in the perivascular areas of
the tumour tissue (Matsubara et al, 2013).
Here, we investigate whether TEMs have a role in the
revascularization of the ischemic limb by: (i) determining
whether TEMs are present in the circulation and ischemic
muscle of CLI patients; (ii) examining the functional relation-
ship between TIE2 expression on monocytes and their
proangiogenic activity in vitro and in the ischemic limb
in vivo.RESULTS
TEMs are increased in patients with CLI and are found within
ischemic muscle
We compared TIE2 expression in circulating monocytes from
patients with CLI and matched controls using flow cytometry.
The demographics of the subjects recruited into this study are
listed in Table 1. Patients with CLI were well matched with
controls for age, sex, smoking history and the co-morbidities
associated with peripheral arterial disease, including hyperten-
sion, hyperlipidemia, diabetes and ischemic heart disease
(p> 0.05 by Fisher’s exact test for each). We found that the
proportion of circulating CD14þmonocytes that expressed TIE2EMBO Mol Med (2013) 5, 858–869 was 9-fold and 15-fold greater in CLI patients compared with
age-matched and young controls, respectively (p< 0.0001,
Fig 1A and B, and Supporting Information Fig S1). Circulating
TEM numbers were significantly higher in CLI patients (i.e.
those with ischemic rest pain or gangrene; Rutherford Score 4, 5
and 6) compared with patients with intermittent claudication
[Rutherford Score 3, p< 0.001 by one-way analysis of variance
(ANOVA), p< 0.05 by post-hoc Bonferroni for Rutherford 3 vs.
4, 5 and 6, Fig 1C].
To examine whether this rise in TEMs in CLI patients was a
specific response to tissue ischemia, circulating TEMs were
measured in a group of CLI patients prior to and 12 weeks
after successful removal of the ischemic stimulus by either
revascularization or amputation of the affected limb. Circulating
TEM numbers in these patients fell to levels seen in controls
(p< 0.004, Fig 1D).
Expression of the TIE2 transcript in TEMs was confirmed
using quantitative PCR after fluorescence-activated cell sorting
(FACS) of TIE2þ and TIE2 monocytes from blood (Fig 1E and
F). Monocytes were further separated according to their
expression of CD14 and CD16 into the three main monocyte
subsets previously described; classical (CD14þþCD16), non-
classical (CD14þCD16þ) and intermediate (CD14þþCD16þ)
(Geissmann et al, 2010). The majority of TEMs (82 5%) fell
within the CD16þ monocyte population, suggesting that TIE2
expression on monocytes is associated with a non-classical/
intermediate monocyte phenotype (Fig 1G).
We also located and quantified TEMs in distal (ischemic) and
proximal (normoxic) muscle biopsies from the limbs of CLI
patients by immunofluorescence staining of frozen sections or
flow cytometric analysis of enzymatically-digested specimens.
Greater numbers of TIE2þ macrophages were present in
ischemic (11.3 2.2%) compared with normoxic muscle from
the same individuals (4.5 1.3%. p< 0.05, Fig 2A–H).2013 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO. 859
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Figure 1. Changes in circulating and muscle resident TEMs in response to CLI.
A. Representative flow cytometric dot plot of circulating TEMs (top right hand gates) in a patient with CLI (right) compared with an age-matched control (left)
showing a higher proportion of monocytes that express TIE2 in the patient.
B. CLI patients (n¼ 40) have a higher proportion of monocytes expressing TIE2 compared with young (n¼20) and age-matched (n¼ 20) controls (3.520.28%
vs. 0.23 0.04% and 0.39 0.09% respectively). p<0.0001 by two-tailed Mann-Whitney U test. Data are mean SEM.
C. Circulating TEMs are significantly higher in CLI patients (i.e. those with ischemic rest pain or gangrene; Rutherford Score 4, 5 and 6) compared with patients
with intermittent claudication (Rutherford Score 3, p< 0.001 by one-way ANOVA). p< 0.05 by post-hoc Bonferroni for Rutherford 3 versus 4, 5 and 6.
D. Graph shows a significant fall in circulating TEMs after removal of the ischemic stimulus in CLI patients by either surgical revascularization (black lines) or
amputation (red lines). p< 0.005 by two-tailed paired t-test.
E. FACS-sorting of TEMs (top gate, red) and TIE2 monocytes (bottom gate, black). Post-sort purity check (right dot plots) show high purities, 94.5%0.8 for
TEMs (n¼5 samples).
F. RT-PCR traces showing that expression of TIE2 is present in TEM samples after 25 cycles but is absent in TIE2monocytes. n¼8 CLI patients, TIE2þ and TIE2
samples analysed in triplicate.
G. (i) Gating of the whole monocyte population (red gate) for phenotyping according to CD14 and CD16 expression shows the typical distribution of classical
(CD14þþCD16 bottom right quandrant), intermediate (CD14þþCD16þ, top right quadrant) and non-classical (CD14þCD16þ, top left quadrant) monocytes.
(ii) Gating of TEMs (red gate) for phenotyping according to CD14 and CD16 expression shows that the majority of these cells express CD16 and are, therefore,
found within either the intermediate or non-classical subset.
860TEMs have proangiogenic activity and respond to
angiopoietin stimulation
TEMs are known to have proangiogenic functions both in vitro
and in vivo (Coffelt et al, 2010; De Palma et al, 2005) but the
activity of TEMs isolated from aged CLI patients with multiple
co-morbidities has not previously been investigated. TEMs
isolated from the blood of CLI patients and co-cultured with
HUVECs on Matrigel exhibited a greater capacity to enhance 2013 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO.HUVEC tubule formation compared with TIE2monocytes from
the same individuals (p< 0.05, Fig 3A and B). Having identified
differences in the numbers and proangiogenic activity of
circulating and muscle-resident TEMs between CLI and controls,
we next measured a panel of circulating angiogenic and
proinflammatory factors in the plasma of CLI patients and
compared this with controls (Table 2). The levels of angiopoie-
tin-2 (ANG2, a TIE2 ligand), vascular endothelial growth factorEMBO Mol Med (2013) 5, 858–869
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Figure 2. Quantification of TIE2R macrophages in human muscle specimens.
A. Muscle specimens were enzymatically digested and analysed by flow cytometry. Gating (red gates) of CD45 positive cells (i) followed by exclusion of lineage
(CD19, CD56, CD3) positive cells (ii), exclusion of doublets (iii) and selection of CD68þ macrophages (iv).
B. Gate for TIE2 expression set according to staining with FMO sample (left). Example TIE2 staining of cells from healthy muscle (middle) and ischemic muscle
(right) showing a higher proportion of TIE2þ macrophages in the ischemic compared with normal tissue.
C. Histogram (gated on CD68þ macrophages) showing higher expression of TIE2 in macrophages from ischemic (red) compared with healthy (blue) muscle.
D. Flow cytometry analysis of digested muscle specimens shows higher proportion of CD68þ macrophages expressing TIE2 in distal ischemic muscle compared
with proximal healthy muscle biopsies from CLI patients (11.32.2% vs. 4.51.3%, respectively). p<0.05 by paired t-test.
E. H&E sections of normoxic (top) muscle compared with ischemic (bottom) muscle which shows loss of the normal muscle architecture and cellular infiltrate.
Scale bars represent 50 mm.
F. Immunofluorescence stains of a section of ischemic muscle showing nucleated cells (blue) expressing CD14 (green) and TIE2 (red) near a blood vessel lined
with TIE2-expressing endothelial cells (arrows). Merged image shows TEMs (orange, arrows).
G. Section of ischemic muscle showing nucleated cells (blue) expressing CD68 (green) and TIE2 (red). Merged image shows macrophages expressing TIE2 (orange,
arrows).
H. Section of healthy muscle showing less frequent nucleated cells (blue) expressing CD68 (green) and TIE2 (red). TIE2-expresssing macrophages are not readily
seen. Scale bars represent 50 mm.(VEGF) and soluble TIE2 (sTIE2) were significantly raised in
CLI patients compared with matched controls (p< 0.05 for all).
Levels of angiopoietin-1 (ANG1) were also twofold higher in
CLI patients compared with controls. ANG1 and ANG2
phosphorylate the TIE2 receptor in endothelial cells and
ANG2 in particular regulates proangiogenic gene expression
in TEMs (Coffelt et al, 2010). We, therefore, stimulated
peripheral blood mononuclear cells (PBMCs) from CLI patients
with both ANG1 and ANG2 and used intracellular flow
cytometric analysis to measure downstream signalling in orderEMBO Mol Med (2013) 5, 858–869 to determine whether the TIE2 receptor is functional in TEMs
from patients with CLI. Both angiopoietins phosphorylated
the TIE2 receptor on these cells, resulting in activation of the
downstream phosphokinases, ERK and AKT (Fig 3C).
Characterization of TEMs in a mouse model of hindlimb
ischemia (HLI)
We next determined whether the TEM kinetics we had observed
in patients with CLI would be recapitulated in a mouse model of
severe HLI that simulates CLI in man. In this model the proximal2013 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO. 861
Research Article www.embomolmed.org
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Figure 3. Proangiogenic activity of TEMs.
A. Typical example of tubules formed following co-culture of HUVECs with TEMs from a CLI patient (left) compared with TIE2 monocytes from the same
individual (right).
B. Overall, there is greater tubule formation (for both tubule length and area) when HUVECs are co-cultured with TEMs compared with TIE2 monocytes. Each
assay performed in triplicate; cells obtained from five CLI patients and five matched-controls. Fold-change in tubule formation was calculated by comparing
tubule growth with control (HUVECs alone) tubules in the same assay. Values shown are mean SEM. p<0.05 by 2-tailed t-test.
C. Histograms show phosphorylation of TIE2 and downstream ERK and AKT signalling in TEMs (upper gate in red) and TIE2 monocytes (lower gate in red) in
unstimulated samples (upper histograms) compared with ANG1 and ANG2-stimulated samples (lower histograms). Stimulation with ANG1 and ANG2 induces
phosphorylation of TIE2, ERK and AKT in TEMs but not in TIE2 monocytes. Phosphorylation measured as fold-change in median-fluorescence intensity of
staining. Representative histograms, n¼ 5 for each, performed in duplicate.
862and distal femoral artery (and its branches) are ligated and
the intervening segment is excised, causing marked hypo-
perfusion of the lower leg and foot, resulting in gangrene of
the toes (Supporting Information Fig S2A). Flow cytometry
(Supporting Information Fig S2B-D) showed a 3.5-fold
increase in the proportion of circulating TEMs (defined as
TIE2þCD11bþCD115þ monocytes) after induction of HLI at
7 days (1.88 0.38% vs. 0.52 0.16%, p< 0.001 by post-hoc
Bonferroni) and 14 days (1.92 0.19% vs. 0.54 0.03%,
p< 0.001 by post-hoc Bonferroni, for HLI and sham, respec-
tively). This mirrored a twofold increase in the numbers
of TIE2þ tissue-resident macrophages (CD45þCD11bþF4/80þ 2013 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO.cells) in ischemic, compared with normoxic, muscle at 7 days
(16.46 1.92% vs. 8.52 1.41%, p< 0.05 by post-hoc
Bonferroni) and a threefold increase at 14 days (28.16 3.35%
vs. 9.03 2.35%, p< 0.001 by post-hoc Bonferroni, Fig 4A); a
result that was strikingly similar to the cellular response seen
in CLI patients.
Silencing of Tie2 in circulating TEMs impairs
revascularization of the ischemic murine hindlimb
Selective elimination of TEMs in tumour-bearing mice impairs
angiogenesis and slows tumour growth (De Palma et al, 2005).
Furthermore, the expression of TIE2 on these cells has beenEMBO Mol Med (2013) 5, 858–869
www.embomolmed.org Research Article
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ANG1 37711418 74422463 ns
ANG2 1973247 4354661 <0.05
FGF 29 10 4019 ns
PLGF 11 4 134 ns
VEGFR1 91 28 689 ns
VEGFR2 68241038 65571008 ns
VEGF 63 21 297 117 <0.05
sTIE2 19,500 1400 25,900 1900 <0.05
PECAM-1 49,763 3312 68,571 8820 <0.05
VCAM-1 325,81657,555 403,462 52,218 ns
IL-4 1.8 0.1 1.50.1 ns
IL-10 11.96.4 2.50.6 ns
IL-6 17 6 7929 <0.05
TNF-a 4.4 0.4 6.72.0 ns
MCP-1 35388 295 53 ns
MCSF 14 1 3911 <0.05
GMCSF 3.591.3 8.79 4.3 ns
SDF-1 33480 387 68 ns
Levels of ANG2, VEGF, sTIE2, PECAM-1, IL-6 and MCSF were significantly
higher in CLI. n¼10 subjects per group. p<0.05 by Mann-Whitney U test. ns:
not statistically significant.shown to be important for their proangiogenic function in
tumours (Mazzieri et al, 2011). We, therefore, investigated the
effect of silencing monocyte TIE2 expression on resolution of
HLI in the mouse to determine whether TIE2 expression on
TEMs is also important for their role in revascularizing the
ischemic limb. We used an inducible lentiviral vector (LV)-
based platform previously described (Mazzieri et al, 2011) to
knockdown Tie2 in TEMs (Fig 4B). Briefly, we replaced the
stem sequence of microRNA-223 with small interfering RNA
(siRNA) sequences targeting Tie2 to generate the artificial
microRNA, amiR(Tie2); we also generated a control amiR
targeting Luciferase, termed amiR(Luc). These LV constructs,
expressing the marker gene orange fluorescent protein (OFP),
were transduced ex vivo into BM-derived hematopoietic stem/
progenitor cells (HS/PC) obtained from transgenic FVB/Pgk-
rtTA-miR-126T mice, generated by LV-mediated transgenesis
(Mazzieri et al, 2011). Transduced/transgenic cells were used to
reconstitute the BM of lethally irradiated FVB mice. In these
mice, Tie2 expression can be conditionally silenced specifically
in mature hematopoietic cells by suppressing expression of the
rtTA in HS/PCs through endogenous miR-126 activity. Effective
Tie2 silencing was confirmed by showing that the Tie2 transcript
levels were significantly down-regulated in FACS-sorted OFPþ
myeloid cells (vs. OFP cells) obtained from doxycycline-treated
amiR(Tie2) but not amiR(Luc) mice (Fig 4C and Supporting
Information Fig S3). Remarkably, doxycycline-induced silen-
cing of Tie2 in TEMs inhibited the endogenous ‘rebound’
angiogenic response that normally recovers blood perfusion to
the ischemic limb over a 28 day period in this model (Fig 4D
and E, p< 0.0001 by two-way ANOVA). Indeed, laser Doppler
imaging showed that, at day 7 post-ischemia, there was aEMBO Mol Med (2013) 5, 858–869 significantly lower paw perfusion index in mice in which
Tie2 was silenced in TEMs (p< 0.05 by post-hoc Bonferroni
test), and this difference persisted throughout the course of
the study up to day 28 (p< 0.01). This also corresponded
with significantly reduced capillary:fibre ratio in gastrocnemius
muscle tissue harvested at the end of the experiment and
analysed histologically in amiR(Tie2) compared with control
mice (Fig 4F and G, p< 0.001 by Mann-Whitney U test). These
findings indicate that the TIE2 receptor functionally contributes
to the proangiogenic activity of TEMs in the ischemic skeletal
muscle and that these cells have an important role in
revascularization of the limb.
Delivery of TEMs into the ischemic hindlimb accelerates
revascularization and improves limb salvage
We then investigated the therapeutic potential of TEMs in the
HLI model by enforcing the expression of TIE2 on BM-derived
macrophages (BMDMs) using a Pgk-Tie2 LV (Fig 5A). The
enforced expression of TIE2 in murine CD11bþ BMDMs was
confirmed by flow cytometry (Fig 5B and C). TIE2-expressing
or control BMDMs (5 105 per group) were injected into
the adductor muscle of the ischemic hindlimb and revascular-
ization was measured using laser Doppler. Delivery of
TIE2-expressing BMDMs enhanced revascularization of the
ischemic limb compared with wild-type BMDMs (Fig 5D and E).
We then investigated whether TEMs isolated from CLI
patients have a similar capacity to stimulate revascularization
of the ischemic hindlimb. Injection of TEMs (5 105 per group)
from CLI patients into the ischemic hindlimbs of nude, athymic
mice similarly protected against limb loss compared with
animals injected with TIE2 monocytes isolated from the same
patients (Fig 5F). The hindlimb salvage rate after injection
of TEMs from CLI patients was 80% compared with 20 and
0% after delivery of TIE2 monocytes and vehicle control,
respectively.DISCUSSION
TIE2-expressing monocytes are thought to be important for the
development of tumour blood vessels and have been highlighted
as a potential target to inhibit tumour angiogenesis and growth
(De Palma et al, 2007). In this study, we show that while
circulating TEM numbers are over 10-fold higher in patients
with CLI than in matched controls, the difference in muscle,
although significant, is less pronounced. Poor limb perfusion
following the onset of critical ischemia may indeed limit TEM
recruitment to the ischemic limb, and possibly explain why
TEMs do not obviously rescue the ischemic limb in CLI patients.
Poor limb perfusion could also account for the lack of muscle
revascularization in spite of the increased levels of circulating
angiogenic factors (such as VEGF and ANG2) in patients
with CLI. Furthermore, it is also possible that recruited TEMs
do not survive in the hostile environment of the ischemic
muscle shortly after recruitment. It is important to note that the
increase in circulating TEM numbers was only associated with
the presence of critical ischemia rather than with its severity2013 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO. 863
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TIE2 monocytes in limb ischemia
Figure 4. TIE2-expressing monocytes/macrophages are upregulated following HLI; silencing their expression of Tie2 inhibits revascularization.
A. Significant increase in circulating TEMs and muscle-resident TIE2þmacrophages following HLI at day 7 and day 14. p< 0.05 versus sham for same timepoint;
p<0.05 versus HLI at day 3 by one-way ANOVA. n¼ 5–7 mice per group.
B. Schematic diagram of double-lentiviral siRNA-mediated knockdown of Tie2 expression.
C. RT-PCR analysis to measure Tie2 expression in transduced (OFPþ) and untransduced (OFP) myeloid cells isolated from the spleens of both amiR(Tie2) and
amiR(Luc) mice (4 weeks after HLI induction; n¼ 9 mice/group). The plots show the dCt mean values for each sample. Significant reduction of Tie2 expression
was found in the amiR(Tie2) group compared with the amiR(Luc) group for OFPþ (right) and not OFP (left) myeloid cells. p<0.002 by Mann-Whitney U test.
n¼ 3 biological samples per group; each sample has been analysed in duplicate and represents a pool of cells from 3 mice. Error bars represent SEM.
D. Laser Doppler images of paw perfusion in representative control (left) and TIE2 knockdown (right) mice following unilateral HLI. Images show faster recovery of
paw perfusion in the controls compared with the TIE2 knockdown mice.
E. Perfusion index graph shows a significant reduction in paw perfusion following knockdown of TIE2 in TEMs (red line) compared with control mice (blue line);
p< 0.0001 by two-way ANOVA. Post-hoc Bonferroni tests: p< 0.05; p<0.001; p<0.01. n¼ 8–10 mice per group.
F. Mouse gastrocnemius muscle stained for CD31 (red) and laminin (green) and used to calculate capillary:fibre (C:F) ratio (outline of muscle fibres appear green
and capillaries, that stain for both, appear orange). The C:F ratio is reduced in muscle from a Tie2 knockdown mouse compared with a control.
G. Overall, a significantly lower C:F ratio in the muscle of TIE2 knockdown mice compared with control mice (n¼ 5 mice/group). p< 0.001. Scale bars represent
100 mm.
864(assessed by Rutherford category). There were no other clinical
correlates (such as diabetes or age) with circulating TEM
numbers.
The data from the present study suggest that TEMs fall into
both CD16þ monocyte subsets identified based on the intensity
of expression of CD14, i.e., non-classical CD14þCD16þ and
intermediate CD14þþCD16þ cells. The intermediate monocyte
subset was shown to differentially express high levels of TIE2 as 2013 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO.well as several other proangiogenic genes, including endoglin
(EDG1) and VEGFR2 (Zawada et al, 2011).
We also provide in vivo evidence that TEMs have a role in
regulating neovascularization in limb ischemia. Monocytes are
the only sizable mononuclear cell population that express TIE2
in the circulation, and the selective elimination of TEMs in
tumour-bearing mice impairs angiogenesis and slows tumour
growth (De Palma et al, 2005). Silencing the expression of TIE2EMBO Mol Med (2013) 5, 858–869
www.embomolmed.org Research Article
Ashish S. Patel et al.
Figure 5. Delivery of (i) murine bone marrow derived TIE2R macrophages and (ii) TEMs from CLI patients into the ischemic hindlimb accelerates
revascularization.
A. Schematic diagram showing generation of TIE2þ BMDMs via LV-mediated transduction of Pgk-Tie2 lentivirus and delivery of these cells into the ischemic
hindlimb 24 h following induction of HLI. Limb perfusion was then imaged at days 3, 7, 14, 21 and 28.
B. CD11b-expression of cultured HSCs following Pgk-Tie2 transduction (red gate) versus control BMDMs (blue gate).
C. Histogram shows marked upregulation of TIE2 expression on Pgk-Tie2 BMDMs (red) compared with control cells (blue).
D. Laser Doppler images of paw perfusion in representative ischemic hindlimbs injected with control BMDMs (left) and Pgk-Tie2 BMDMs (right) showing
accelerated recovery of paw perfusion in the Pgk-Tie2 treated group.
E. Paw perfusion index graph shows significantly faster paw perfusion recovery following delivery of Pgk-Tie2 BMDMs (red) compared with control BMDMs
(blue line); p< 0.0001 by two-way ANOVA. Post-hoc Bonferroni tests: p< 0.05; p<0.01. n¼ 8–10 mice per group.
F. Increased salvage of ischemic hindlimbs of nude, athymic mice following delivery of human TEMs (80%, n¼4/5) compared with TIE2 monocytes
(20%, n¼1/5) and vehicle control (0%, n¼ 0/5).on TEMs impaired the restoration of blood flow to the ischemic
hindlimb and this impairment persisted throughout the course
of the experiment, suggesting that TEMs have an important
role in revascularization of ischemic tissue. Direct delivery
of murine BMDMs overexpressing TIE2 into the ischemic
hindlimb accelerated the resolution of ischemia (improved
perfusion was noted as early as 48 h after delivery of these
cells), further supporting a role for TEMs in muscle neo-
vascularization. TEMs isolated from CLI patients also prevented
the onset of gangrene and auto-amputation after induction
of HLI in nude mice. These data suggest that TEMs have the
capacity to promote neovascularization in vivo and support
the notion that the lack of an effect in CLI patients, in the face
of large circulating TEM numbers, may be as a result of poor
recruitment to the muscle.EMBO Mol Med (2013) 5, 858–869 The angiogenic hypoxia-inducible factor (HIF) pathway is
activated in ischemic muscle of patients with acute-on-chronic
ischemia (Tuomisto et al, 2004). This results in transcriptional
upregulation of genes containing hypoxia responsive elements,
including VEGF and tumour necrosis factor a (TNF-a), which
promote release of ANG2 by endothelial cells within the
ischemic muscle (Tressel et al, 2008). It is possible, therefore,
that the endothelium is the source of the increased ANG2 levels
we, and others, have measured in the blood (and muscle) of
patients with CLI (Brandao et al, 2011; Findley et al, 2008). We
now show that stimulation of TEMs from CLI patients with
ANG2 (as well as ANG1) induces phosphorylation of the TIE2
receptor and activates downstream signalling. These data
suggest that circulating TEMs have marked proangiogenic
activity and that their ligands, especially ANG2 which is2013 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO. 865
Research Article www.embomolmed.org
TIE2 monocytes in limb ischemia
866increased in the circulation of CLI patients, may regulate
activation of the TIE2 receptor and downstream signalling
in vivo. The raised levels of circulating ANG2 in CLI patients
could enhance the angiogenic activity of TEMs whilst they are in
the circulation before they infiltrate the ischemic muscle as
shown by Hamm et al (2013) and others (Coffelt et al, 2010).
TIE2-expressing monocytes do not express the chemokine (C-C
motif) receptor 2 (CCR2) and, rather than responding to CCL2
(formerly MCP-1), are recruited to sites of active neovascular-
ization in close proximity to blood vessels via ANG2/TIE2
interactions (Mazzieri et al, 2011). Following migration into
ischemic muscle, tissue-resident TEMs are likely to be further
modulated within the hypoxic microenvironment, where they
may promote endothelial cell survival and vascular remodel-
ling. The regulation of TEM function by hypoxia-driven
pathways in CLI is also supported by recent evidence that
F4/80þmacrophages in PHD2þ/mice are already skewed to an
‘M2-type’ phenotype, have higher TIE2 expression, and induce
greater collateral vessel growth following induction of HLI
(Takeda et al, 2011). In the developing embryo, macrophages
expressing TIE2 support the formation of blood vessels by
physically promoting fusion of sprouting endothelial tips
cells via direct cell-to-cell contacts, in a non-canonical, VEGF-
independent fashion (Fantin et al, 2010). These cells may have a
similar role in providing a scaffold and/or paracrine support
during vascular maturation within ischemic tissues.
ANG2 is also important in ‘priming’ the vasculature for
angiogenesis by inducing pericyte detachment to destabilize
the vessels and increase vascular permeability, which (in the
presence of VEGF) promotes endothelial tip-cell sprouting.
There is, however, conflicting evidence for the role of
ANG2 in ischemia-induced vascular remodelling as its over-
expression in endothelial cells has been shown to impair
revascularization (Reiss et al, 2007). Our studies reveal the
presence of an angiogenic drive in the circulation of patients
with CLI, with raised levels of VEGF and ANG2. The latter may
be responsible for the upregulation of TIE2 expression that we
have measured in circulating monocytes in CLI patients. There is
also evidence from other studies that ANG2 enhances the
expression of proangiogenic genes (e.g. matrix metalloprotei-
nase9, MMP9) or ‘M2’ markers on monocytes (Coffelt et al,
2010).
We have shown that TEMs have proangiogenic activity when
delivered into ischemic tissues, hence these cells may deserve
further investigation as a potential candidate for cell therapy
to promote neovascularization in CLI. Their relatively low
abundance in the circulation is, however, an obstacle to their
clinical use. This may be overcome in a number of ways. For
example, mononuclear cells can be primed with cartilage
oligomeric matrix protein-ANG1 (COMP-ANG1) prior to
delivery; this was shown to upregulate TIE2 expression on
monocytes and to stimulate neovascularization in the ischemic
hindlimb (Kim et al, 2009). BMNCs can also be differentiated
into TIE2þCD11bþ myeloid cells in vitro and used to
successfully treat the ischemic hindlimbs of diabetic mice
(Jeong et al, 2009). Moreover, TEM-like proangiogenic mono-
cytes/macrophages generated from human embryonic stem 2013 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO.cells can also stimulate remodelling and vessel maturation
(Klimchenko et al, 2011) and may be used as an alternative and
abundant source of these cells.MATERIALS AND METHODS
An expanded description of the methods used is available in the
Supporting Information.
Characteristics of patients and controls
Patients with CLI, matched controls and young healthy controls were
recruited into this study. Patients with chronic renal failure, a history
of malignancy or those taking steroids were excluded. Matched
controls were volunteers without clinical evidence of peripheral
vascular disease. Venous blood was taken from the antecubital fossa
prior to and 12-weeks after intervention to treat CLI (angioplasty,
bypass or amputation). Muscle biopsy specimens were taken from
patients undergoing lower limb amputation surgery; the normoxic
muscle biopsy was taken from the proximal, healthy portion of the
leg and the ischemic biopsy from muscle at the distal part of the
amputated portion of the limb.
Quantification of TEMs in blood and muscle
TEMs were quantified in blood and muscle from CLI patients and after
induction of HLI in mice (see Supporting Information). Human and
murine blood and muscle samples were analysed using flow
cytometry. Human monocytes, identified as lineage (CD3,CD56,CD19)
negative cells that expressed CD14, were quantified for their
expression of TIE2. Murine monocytes were identified as lineage
(CD3,CD19,Ly6G,NK1.1) negative, CD11bþCD115þ cells and quanti-
fied for their expression of TIE2.
Human healthy and ischemic muscle biopsies and murine crural muscle
samples were digested by incubation in collagenase IV, DNAse and
hyaluronidase at 378C for 30min followed by trituration and filtration
through a 70mM nylon mesh. Cell suspensions were washed and
blocked with the appropriate blocking antibodies prior to staining. Cells
obtained from human muscle were fixed with 2% paraformaldehyde
and permeabilized with saponin (Perm/wash buffer, BD Biosciences) for
intracellular staining of CD68. Human macrophages were identified as
lineage negative CD45þCD68þ cells and quantified for TIE2 expression.
Murine macrophages were identified as lineage negative
CD45þCD11bþF4/80þ cells and quantified for TIE2 expression.
Intracellular phosphorylation assays were carried out on PBMCs. PBMCs
were isolated from whole blood obtained from CLI patients using Ficoll-
Paque Plus (GE Healthcare), and stimulated with 30ng/mL ANG1
oligomers or 300ng/mL ANG2 (R&D Systems) for 5min at 378C. Cells
were fixed with 2% paraformaldehyde, permeabilized (Perm buffer IV,
BD Biosciences) and phosphorylated TIE2, ERK and AKTwere measured
in TEMs and TIE2 monocytes using flow cytometry.
Flow cytometric data was analysed by FlowJo (Tree Star Inc., USA) and
histograms for phosphorylation studies produced using Cytobank
(Cytobank Inc., USA) software. For more details see Supporting Information.
Isolation of TEMS
Human PBMCs were isolated from 100mLs of venous blood by Ficoll-
Paque. Monocytes were enriched from the PBMCs by immunomagneticEMBO Mol Med (2013) 5, 858–869
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The paper explained
PROBLEM:
Peripheral arterial disease can cause a severe restriction to blood
flow leading to critical limb ischemia (CLI), which manifests as a
constant and intractable pain, often with ulceration or gangrene. In
a third of cases, the limb is not suitable for conventional treatments
(surgery or angioplasty), necessitating amputation. Proangiogenic
cell therapies, aimed at stimulating new blood vessel growth in the
limb, have been used in these ‘no option’ patients for limb salvage
but with disappointing results. There is controversy as to which
cell types are key for promoting therapeutic neovascularization.
Monocytes, known to have a role in both angiogenesis and
arteriogenesis, are one of the candidates. We investigated whether a
subset of monocytes that express TIE2 (TIE2-expressing monocytes,
TEMs) and are pivotal to neovascularization in tumours may also
have a role in the revascularization of the critically ischemic limb.
RESULTS:
This is the first study to show that TEMs are increased both in the
circulation and muscle of patients with CLI. TEM numbers were
also raised in mice following induction of hindlimb ischemia
(HLI). TEMs isolated from CLI patients had greater proangiogenic
activity compared with TIE2-negative monocytes in vitro.
Conditional silencing of Tie2 in TEMs halved the rate of
revascularization following induction of HLI, whereas delivery of
murine macrophages overexpressing TIE2 or human TEMs
isolated from CLI patients rescued limb ischemia and prevented
limb loss.
IMPACT:
Our results show that TEMs have the potential to improve
revascularization of the ischemic limb and may thus
represent a novel cell therapy vehicle for promoting limb
salvage in CLI. Delivering a highly proangiogenic subset of
monocytes, such as TEMs, might be more fruitful in treating
CLI than using whole monocytes or mixed populations of
mononuclear cells.selection using anti-CD14 microbeads (CliniMACS, Miltenyi Biotec).
TIE2þ and TIE2 monocytes (identified according to the panel of
antibodies used above) were then isolated by FACS-sorting (Aria II, BD
Biosciences) ensuring purities of greater than 95%. Expression of TIE2
by TEMs was confirmed using RT-PCR. For more details see Supporting
Information.
Assessment of the proangiogenic potential of human TEMs
Human umbilical vein endothelial cells (HUVECs, 4103) were co-
cultured with FACS-sorted TIE2þ or TIE2 monocytes (2103) on
m-slide angiogenesis plates (Ibidi, Germany) that had been coated
with 10mL per well of growth-factor reduced Matrigel Basement
Membrane Matrix (BD Biosciences). Cells were incubated for 18 h at
378C and 5% CO2 and endothelial tubules photographed under
phase-contrast microscopy. Image-analysis software (Image-Pro Plus,
Media Cybernetics) was used to quantify tubule length and area. Each
experiment was carried out in triplicate. For more details see
Supporting Information.
TEMs (5105), isolated from CLI patients, were injected into the
adductor muscles of nude, athymic mice 24 h after induction of HLI
and limb salvage (compared with TIE2 monocytes and vehicle
control injections) was recorded using paw auto-amputation as the
endpoint.
Measurement of circulating factors in patients with CLI and
controls
Plasma samples, collected from patients with CLI and matched
controls, were analysed for a panel of angiogenic and inflammatory
factors using SearchLight multiplex analysis array (Aushon Biosystems,
USA) and quantikine ELISA kits (R&D systems) following the
manufacturer’s instructions.EMBO Mol Med (2013) 5, 858–869 Recovery of the ischemic hindlimb after Tie2 silencing
and enforced expression of Tie2 in murine monocytes/
macrophages
To knockdown Tie2 in TEMs, we used a previously described inducible
LV-based platform (Mazzieri et al, 2011). Following BM reconstruction
of lethally irradiated mice with transduced/transgenic cells, TIE2
expression was conditionally silenced specifically in mature hemato-
poietic cells using alternate daily doxycycline injections throughout
the experiment. HLI was induced in Tie2 knockdown and Luciferase
control mice and paw perfusion was measured by laser Doppler.
Gastrocnemius muscle specimens were harvested at the end of the
experiment and analysed for capillary:fibre ratio. For more details, see
Supporting Information.
To determine whether TEMs induce revascularization of the ischemic
hindlimb, BMDMs were engineered to overexpress TIE2 using a Pgk-
Tie2 LV. BM cells were obtained by flushing the femurs of mice, plated
and cultured with M-CSF for 5 days to allow monocytic differentiation.
These cells were then transduced with Pgk-Tie2 LVs as described
previously (Amendola et al, 2009).
Statistics
Data were analysed with SPSS version 20 (IBM Corp.) and GraphPad
Prism version 5 (GraphPad Inc.). Statistical analyses were carried out
using Fisher’s exact test, Mann-Whitney U test, paired t-test and one-
way or two-way ANOVA as appropriate. Data from replicate
experiments are represented as mean SEM. A two-tailed P value of
less than 0.05 was considered statistically significant.
Study approval
The clinical study protocols were approved by the local research ethics
committee at Guy’s & St Thomas’ NHS Foundation Trust and registered2013 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO. 867
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868on the UK Clinical Research Network portfolio. All subjects provided
informed written consent prior to their participation in the studies. All
animal studies were performed under (i) the UK Animals (Scientific
Procedures) Act 1986 following approval by the local ethics
committee and (ii) the Animal Care and Use Committee of the San
Raffaele Scientific Institute (IACUC 324, 335, 446, 447).Author contributions
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